SynCardia Completes First In Vivo Implantations of Next-Generation Emperor Total Artificial Heart

Core Insights - Picard Medical has achieved a significant milestone by successfully completing the first in vivo implantations of the Emperor Total Artificial Heart (TAH), marking a major advancement in total artificial heart technology [1][2] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized as the leader in total artificial heart technology for patients with end-stage heart failure [4] - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, and it remains the only commercially available artificial heart in the U.S. and Canada [4] Product Development - The Emperor TAH was successfully implanted in three pre-clinical models, demonstrating full and stable blood circulation, energy efficiency, and operation without technical issues [2][3] - The device exhibited hemodynamic stability, preload sensitivity, and afterload independence, reflecting the natural functioning of a human heart [2][3] - The positive outcomes from the initial implantations validate the engineering choices made for the Emperor platform and support the acceleration of its development [3] Market Position - The successful development of the Emperor platform strengthens Picard Medical's position as a global leader in total artificial hearts and aims to expand the market by offering a fully implantable system with enhanced performance and usability [2][3]